Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0497-0040 · 1 trial · 4 indications
Measured in events
| Arm | Type | Description |
|---|---|---|
| SAD | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD1 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD2 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD3 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD4 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0497-0040 | DRUG | NNC0497-0040 will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
For SAD cohorts Inclusion Criteria: * Female of non-childbearing potential or male aged 18-55 years (both inclusive) at screening. * Body mass index between 18.5 kilogram per m\^2 and 29.9 kilogram per m\^2 (both inclusive) at screening. * Considered to be generally healthy based on the medical hi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC0497-0040 is an investigational small molecule being developed for Type 1 Diabetes (T1D). It is also being studied in participants with overweight or obesity, including those with Type 1 Diabetes who have overweight or obesity. The drug is currently in Phase 1 clinical development.
NNC0497-0040 is being developed by Novo Nordisk A/S, a biopharmaceutical company. Novo Nordisk's stock is listed under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's effects in participants with Type 1 Diabetes and related conditions.
NNC0497-0040 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being studied in a Phase 1 trial that is recruiting participants, and it remains in the early stages of clinical testing.
NNC0497-0040 is being studied in a Phase 1 clinical trial with the identifier NCT07578584. This trial is investigating the drug's effect in healthy participants, participants with overweight or obesity, and participants with Type 1 Diabetes who have overweight or obesity. The trial is recruiting participants in Germany.
Yes, the Phase 1 clinical trial of NNC0497-0040 is randomized, double-blind, and controlled. This means participants are randomly assigned to receive the drug or a control, and neither the participants nor the researchers know which treatment is being administered. The trial is designed to evaluate the drug's effects in a controlled setting.